Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 85

1.

Efficacy of Direct-acting Antivirals for Chronic Hepatitis C Virus Infection in People Who Inject Drugs or Receive Opioid Substitution Therapy: A Systematic Review and Meta-analysis.

Graf C, Mücke MM, Dultz G, Peiffer KH, Kubesch A, Ingiliz P, Zeuzem S, Herrmann E, Vermehren J.

Clin Infect Dis. 2019 Sep 12. pii: ciz696. doi: 10.1093/cid/ciz696. [Epub ahead of print]

PMID:
31513710
2.

Prophylactic percutaneous endoscopic gastrostomy in patients with head and neck cancer: Influence on nutritional status, utilisation rate and complications.

Hausmann J, Kubesch A, Müller von der Grün J, Goettlich CM, Filmann N, Oliver Tal A, Vermehren J, Friedrich-Rust M, Wächtershäuser A, Bojunga J, Blumenstein I.

Int J Clin Pract. 2019 Aug 13:e13405. doi: 10.1111/ijcp.13405. [Epub ahead of print]

PMID:
31408231
3.

Quinolone- and multidrug-resistance predict failure of antibiotic prophylaxis of spontaneous bacterial peritonitis.

Mücke MM, Mayer A, Kessel J, Mücke VT, Bon D, Schwarzkopf K, Rüschenbaum S, Queck A, Göttig S, Vermehren A, Weiler N, Welker MW, Reinheimer C, Hogardt M, Vermehren J, Herrmann E, Kempf VAJ, Zeuzem S, Lange CM.

Clin Infect Dis. 2019 Jun 20. pii: ciz540. doi: 10.1093/cid/ciz540. [Epub ahead of print]

PMID:
31228250
4.

Capnography monitoring of non-anesthesiologist provided sedation during percutaneous endoscopic gastrostomy placement: A prospective, controlled, randomized trial.

Peveling-Oberhag J, Michael F, Tal A, Welsch C, Vermehren J, Farnik H, Grammatikos G, Lange C, Walter D, Blumenstein I, Filmann N, Herrmann E, Albert J, Zeuzem S, Bojunga J, Friedrich-Rust M.

J Gastroenterol Hepatol. 2019 Jun 20. doi: 10.1111/jgh.14760. [Epub ahead of print]

PMID:
31222832
5.

Serum sphingolipids predict de novo hepatocellular carcinoma in hepatitis C cirrhotic patients with sustained virologic response.

Mücke VT, Thomas D, Mücke MM, Waidmann O, Zeuzem S, Sarrazin C, Pfeilschifter J, Vermehren J, Finkelmeier F, Grammatikos G.

Liver Int. 2019 Jun 17. doi: 10.1111/liv.14178. [Epub ahead of print]

PMID:
31207039
6.

miRNA-26b downregulation in peripheral blood mononuclear cells of patients with hepatitis C associated lymphomas is restored by successful interferon-free antiviral therapy.

Peveling-Oberhag J, Bankov K, Dultz G, Ballo O, Lohmeyer J, Brunnberg U, Marcu V, Walter D, Zeuzem S, Hansmann ML, Welzel TM, Vermehren J.

Antivir Ther. 2019 Jun 10. doi: 10.3851/IMP3322. [Epub ahead of print]

PMID:
31180334
7.

Performance of Three Common Hepatitis C Virus (HCV) Genotyping Assays for Identification of HCV Genotype 2/1 Chimeras.

Peiffer KH, Kuhnhenn L, Stelzl E, Dietz J, Susser S, Tal AO, Finkelmeier F, Zuckerman E, Cornberg M, Barak M, Piazzolla V, Mangia A, Zeuzem S, Kessler HH, Vermehren J, Sarrazin C.

J Clin Microbiol. 2019 Jun 25;57(7). pii: e00060-19. doi: 10.1128/JCM.00060-19. Print 2019 Jul.

PMID:
31043467
8.

Efficacy and safety of direct-acting antivirals for hepatitis C in the elderly: A systematic review and meta-analysis.

Mücke MM, Herrmann E, Mücke VT, Graf C, Zeuzem S, Vermehren J.

Liver Int. 2019 Sep;39(9):1652-1660. doi: 10.1111/liv.14126. Epub 2019 May 15.

PMID:
31033122
9.

Treatment strategies for patients with decompensated liver cirrhosis due to hepatitis C virus infection eligible for liver transplantation: real-life data from five German transplant centers.

Sandmann L, Dörge P, Wranke A, Vermehren J, Welzel TM, Berg CP, Grottenthaler JM, Weiss KH, Langel J, Sterneck M, von Wulffen M, Manns MP, Wedemeyer H, Hardtke S, von Hahn T.

Eur J Gastroenterol Hepatol. 2019 Aug;31(8):1049-1056. doi: 10.1097/MEG.0000000000001386.

PMID:
30807443
10.

Absence of HBV Reactivation in Patients With Resolved HBV Infection Following DAA Therapy for Hepatitis C: A 1-Year Follow-up Study.

Mücke MM, Mücke VT, Peiffer KH, Sarrazin C, Zeuzem S, Berger A, Vermehren J.

Open Forum Infect Dis. 2018 Dec 15;6(1):ofy340. doi: 10.1093/ofid/ofy340. eCollection 2019 Jan.

11.

Noninvasive screening identifies patients at risk for spontaneous bacterial peritonitis caused by multidrug-resistant organisms.

Ferstl PG, Müller M, Filmann N, Hogardt M, Kempf VA, Wichelhaus TA, Lange CM, Vermehren J, Zeuzem S, Reinheimer C, Waidmann O.

Infect Drug Resist. 2018 Nov 2;11:2047-2061. doi: 10.2147/IDR.S172587. eCollection 2018.

12.

Feasibility and safety of nivolumab in advanced hepatocellular carcinoma: real-life experience from three German centers.

Finkelmeier F, Czauderna C, Perkhofer L, Ettrich TJ, Trojan J, Weinmann A, Marquardt JU, Vermehren J, Waidmann O.

J Cancer Res Clin Oncol. 2019 Jan;145(1):253-259. doi: 10.1007/s00432-018-2780-8. Epub 2018 Oct 29.

PMID:
30374657
13.

HCV core antigen as an alternative to HCV RNA testing in the era of direct-acting antivirals: retrospective screening and diagnostic cohort studies.

van Tilborg M, Al Marzooqi SH, Wong WWL, Maan R, Vermehren J, Maasoumy B, Mazzulli T, Bolotin S, Garber G, Guerra F, Flud CR, Kowgier M, Janssen HL, de Knegt RJ, Pawlotsky JM, Cloherty GA, Duarte-Rojo A, Sarrazin C, Wedemeyer H, Feld JJ.

Lancet Gastroenterol Hepatol. 2018 Dec;3(12):856-864. doi: 10.1016/S2468-1253(18)30271-1. Epub 2018 Sep 28.

PMID:
30274834
14.

Risk factors for early and late procedure-related adverse events in percutaneous endoscopic gastrostomy: A single center, retrospective study.

Peveling-Oberhag J, Osman I, Walter D, Filmann N, Stratmann K, Hausmann J, Knop V, Waidmann O, Vermehren J, Herrmann E, Zeuzem S, Friedrich-Rust M, Blumenstein I, Albert JG.

J Gastroenterol Hepatol. 2019 Feb;34(2):404-409. doi: 10.1111/jgh.14407. Epub 2018 Aug 23. No abstract available.

PMID:
30070394
15.

Clinical significance of detectable and quantifiable HCV RNA at the end of treatment with ledipasvir/sofosbuvir in GT1 patients.

Maasoumy B, Buggisch P, Mauss S, Boeker KHW, Müller T, Günther R, Zimmermann T, Manns MP, Sarrazin C, Hüppe D, Wedemeyer H, Vermehren J.

Liver Int. 2018 Nov;38(11):1906-1910. doi: 10.1111/liv.13932. Epub 2018 Aug 10.

PMID:
30022590
16.

Circulating hypoxia marker carbonic anhydrase IX (CA9) in patients with hepatocellular carcinoma and patients with cirrhosis.

Finkelmeier F, Canli Ö, Peiffer KH, Walter D, Tal A, Koch C, Pession U, Vermehren J, Trojan J, Zeuzem S, Piiper A, Greten FR, Grammatikos G, Waidmann O.

PLoS One. 2018 Jul 16;13(7):e0200855. doi: 10.1371/journal.pone.0200855. eCollection 2018.

17.

Challenges and perspectives of direct antivirals for the treatment of hepatitis C virus infection.

Vermehren J, Park JS, Jacobson IM, Zeuzem S.

J Hepatol. 2018 Nov;69(5):1178-1187. doi: 10.1016/j.jhep.2018.07.002. Epub 2018 Jul 11. Review.

PMID:
30006068
18.

Risk of de novo Hepatocellular Carcinoma after HCV Treatment with Direct-Acting Antivirals.

Finkelmeier F, Dultz G, Peiffer KH, Kronenberger B, Krauss F, Zeuzem S, Sarrazin C, Vermehren J, Waidmann O.

Liver Cancer. 2018 May;7(2):190-204. doi: 10.1159/000486812. Epub 2018 Mar 1.

19.

Editorial: genotype 3 HCV-who still needs ribavirin in a pan-genotypic era? Authors' reply.

von Felden J, Vermehren J, Schulze Zur Wiesch J, Sarrazin C, Christensen S.

Aliment Pharmacol Ther. 2018 Jun;47(11):1550-1551. doi: 10.1111/apt.14648. No abstract available.

PMID:
29878436
20.

Letter: adoption of uniform nomenclature is crucial for estimating the true risk of HBV reactivation in patients treated with direct-acting antivirals for hepatitis C.

Mücke MM, Mücke VT, Vermehren J.

Aliment Pharmacol Ther. 2018 Jun;47(11):1573-1574. doi: 10.1111/apt.14653. No abstract available.

PMID:
29878415
21.

Impact of HBV genotype and mutations on HBV DNA and qHBsAg levels in patients with HBeAg-negative chronic HBV infection.

Kuhnhenn L, Jiang B, Kubesch A, Vermehren J, Knop V, Susser S, Dietz J, Carra G, Finkelmeier F, Grammatikos G, Zeuzem S, Sarrazin C, Hildt E, Peiffer KH.

Aliment Pharmacol Ther. 2018 Jun;47(11):1523-1535. doi: 10.1111/apt.14636. Epub 2018 Apr 10.

PMID:
29637585
22.

Interferon-free treatment choice according to baseline RASs leads to high SVR rates in HCV genotype 1 infected patients.

Peiffer KH, Vermehren J, Kuhnhenn L, Susser S, Dietz J, Finkelmeier F, Weiler N, Welzel T, Grammatikos G, Zeuzem S, Sarrazin C.

J Infect Chemother. 2018 Jul;24(7):524-530. doi: 10.1016/j.jiac.2018.02.008. Epub 2018 Apr 5.

PMID:
29628383
23.

High efficacy of sofosbuvir/velpatasvir and impact of baseline resistance-associated substitutions in hepatitis C genotype 3 infection.

von Felden J, Vermehren J, Ingiliz P, Mauss S, Lutz T, Simon KG, Busch HW, Baumgarten A, Schewe K, Hueppe D, Boesecke C, Rockstroh JK, Daeumer M, Luebke N, Timm J, Schulze Zur Wiesch J, Sarrazin C, Christensen S.

Aliment Pharmacol Ther. 2018 May;47(9):1288-1295. doi: 10.1111/apt.14592. Epub 2018 Mar 14.

PMID:
29536554
24.

Divergent preS Sequences in Virion-Associated Hepatitis B Virus Genomes and Subviral HBV Surface Antigen Particles From HBV e Antigen-Negative Patients.

Peiffer KH, Kuhnhenn L, Jiang B, Mondorf A, Vermehren J, Knop V, Susser S, Walter D, Dietz J, Carra G, Finkelmeier F, Zeuzem S, Sarrazin C, Hildt E.

J Infect Dis. 2018 Jun 5;218(1):114-123. doi: 10.1093/infdis/jiy119.

PMID:
29528436
25.

Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: a systematic review and meta-analysis.

Mücke MM, Backus LI, Mücke VT, Coppola N, Preda CM, Yeh ML, Tang LSY, Belperio PS, Wilson EM, Yu ML, Zeuzem S, Herrmann E, Vermehren J.

Lancet Gastroenterol Hepatol. 2018 Mar;3(3):172-180. doi: 10.1016/S2468-1253(18)30002-5. Epub 2018 Jan 19. Review.

PMID:
29371017
26.

Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals.

Dietz J, Susser S, Vermehren J, Peiffer KH, Grammatikos G, Berger A, Ferenci P, Buti M, Müllhaupt B, Hunyady B, Hinrichsen H, Mauss S, Petersen J, Buggisch P, Felten G, Hüppe D, Knecht G, Lutz T, Schott E, Berg C, Spengler U, von Hahn T, Berg T, Zeuzem S, Sarrazin C; European HCV Resistance Study Group.

Gastroenterology. 2018 Mar;154(4):976-988.e4. doi: 10.1053/j.gastro.2017.11.007. Epub 2017 Nov 13.

PMID:
29146520
27.

Real-world effectiveness of 8-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C.

Buggisch P, Vermehren J, Mauss S, Günther R, Schott E, Pathil A, Boeker K, Zimmermann T, Teuber G, Vornkahl HP, Simon KG, Niederau C, Wedemeyer H, Zeuzem S.

J Hepatol. 2018 Apr;68(4):663-671. doi: 10.1016/j.jhep.2017.11.009. Epub 2017 Nov 11.

PMID:
29133244
28.

Liver transplantation for chronic hepatitis C virus infection in the United States 2002-2014: An analysis of the UNOS/OPTN registry.

Dultz G, Graubard BI, Martin P, Welker MW, Vermehren J, Zeuzem S, McGlynn KA, Welzel TM.

PLoS One. 2017 Oct 31;12(10):e0186898. doi: 10.1371/journal.pone.0186898. eCollection 2017.

29.

Letter: low rates of HBV serology testing in patients with chronic hepatitis C receiving direct acting antivirals - Authors' reply.

Mücke MM, Mücke VT, Vermehren J.

Aliment Pharmacol Ther. 2017 Nov;46(9):909-910. doi: 10.1111/apt.14286. No abstract available.

30.

Letter: the potential risk of HBV reactivation in patients with resolved HBV infection during direct-acting antiviral therapy - authors' reply.

Mücke MM, Mücke VT, Vermehren J.

Aliment Pharmacol Ther. 2017 Oct;46(7):703-704. doi: 10.1111/apt.14259. No abstract available.

31.

Effects of oral Δ9-tetrahydrocannabinol on the cerebral processing of olfactory input in healthy non-addicted subjects.

Walter C, Oertel BG, Felden L, Nöth U, Vermehren J, Deichmann R, Lötsch J.

Eur J Clin Pharmacol. 2017 Dec;73(12):1579-1587. doi: 10.1007/s00228-017-2331-2. Epub 2017 Sep 2.

PMID:
28866743
32.

Commutability and concordance of four hepatitis B virus DNA assays in an international multicenter study.

Maasoumy B, Bremer B, Lehmann P, Marins EG, Michel-Treil V, Simon CO, Njoya M, Cornberg M, Paxinos E, Manns MP, Vermehren J, Sarrazin C, Sohn JY, Cho Y, Wedemeyer H.

Therap Adv Gastroenterol. 2017 Aug;10(8):609-618. doi: 10.1177/1756283X17722745. Epub 2017 Aug 7.

33.

Hepatocellular carcinoma recurrence after direct antiviral agent treatment: A European multicentre study.

Kolly P, Waidmann O, Vermehren J, Moreno C, Vögeli I, Berg T, Semela D, Zeuzem S, Dufour JF.

J Hepatol. 2017 Oct;67(4):876-878. doi: 10.1016/j.jhep.2017.07.007. Epub 2017 Jul 19. No abstract available.

PMID:
28733219
34.

No evidence of hepatitis B virus reactivation in patients with resolved infection treated with direct-acting antivirals for hepatitis C in a large real-world cohort.

Mücke VT, Mücke MM, Peiffer KH, Weiler N, Welzel TM, Sarrazin C, Zeuzem S, Berger A, Vermehren J.

Aliment Pharmacol Ther. 2017 Aug;46(4):432-439. doi: 10.1111/apt.14177. Epub 2017 Jun 19.

35.

Comparison of on-treatment HCV RNA during direct antiviral therapy using two different COBAS TaqMan HCV assays.

Vermehren J, Bourlière M, Pol S, Marcellin P, Hyland RH, Jiang D, Brainard DM, Zeuzem S, Welzel TM.

J Clin Virol. 2017 Apr;89:51-56. doi: 10.1016/j.jcv.2017.02.008. Epub 2017 Feb 24.

PMID:
28259054
36.

Conversion From Sirolimus to Everolimus in Long-Term Liver Graft Recipients.

Weiler N, Bilge N, Troetschler S, Vermehren J, Schnitzbauer AA, Herrmann E, Sarrazin C, Zeuzem S, Welker MW.

J Clin Pharmacol. 2017 Jul;57(7):837-845. doi: 10.1002/jcph.871. Epub 2017 Jan 30.

PMID:
28134984
37.

Multicenter Comparison Study of both Analytical and Clinical Performance across Four Roche Hepatitis C Virus RNA Assays Utilizing Different Platforms.

Vermehren J, Stelzl E, Maasoumy B, Michel-Treil V, Berkowski C, Marins EG, Paxinos EE, Marino E, Wedemeyer H, Sarrazin C, Kessler HH.

J Clin Microbiol. 2017 Apr;55(4):1131-1139. doi: 10.1128/JCM.02193-16. Epub 2017 Jan 25.

38.

To treat or not to treat - Successful hepatitis C virus eradication in a patient with advanced hepatocellular carcinoma and complete response to sorafenib.

Waidmann O, Peveling-Oberhag J, Eichler K, Schulze F, Vermehren J.

Z Gastroenterol. 2017 Jun;55(6):564-568. doi: 10.1055/s-0042-118232. Epub 2016 Nov 2.

PMID:
27806410
39.

Hepatitis C RNA assay differences in results: Potential implications for shortened therapy and determination of Sustained Virologic Response.

Cloherty G, Chevaliez S, Sarrazin C, Herman C, Holzmayer V, Dawson G, Maasoumy B, Vermehren J, Wedemeyer H, Feld JJ, Pawlotsky JM.

Sci Rep. 2016 Oct 20;6:35410. doi: 10.1038/srep35410.

40.

Reply to: "HCV RNA kinetics on-treatment do not predict sustained virologic response in HCV genotype 3 patients receiving sofosbuvir and ribavirin".

Maasoumy B, Vermehren J, Wedemeyer H, Sarrazin C.

J Hepatol. 2016 Nov;65(5):1059-1060. doi: 10.1016/j.jhep.2016.07.018. Epub 2016 Jul 25. No abstract available.

PMID:
27460833
41.

Diagnostics in hepatitis C: The end of response-guided therapy?

Maasoumy B, Vermehren J.

J Hepatol. 2016 Oct;65(1 Suppl):S67-S81. doi: 10.1016/j.jhep.2016.07.023. Review.

PMID:
27641989
42.

The efficacy and safety of direct acting antiviral treatment and clinical significance of drug-drug interactions in elderly patients with chronic hepatitis C virus infection.

Vermehren J, Peiffer KH, Welsch C, Grammatikos G, Welker MW, Weiler N, Zeuzem S, Welzel TM, Sarrazin C.

Aliment Pharmacol Ther. 2016 Oct;44(8):856-65. doi: 10.1111/apt.13769. Epub 2016 Aug 23.

43.

Regression of fibrosis and portal hypertension in HCV-associated cirrhosis and sustained virologic response after interferon-free antiviral therapy.

Knop V, Hoppe D, Welzel T, Vermehren J, Herrmann E, Vermehren A, Friedrich-Rust M, Sarrazin C, Zeuzem S, Welker MW.

J Viral Hepat. 2016 Dec;23(12):994-1002. doi: 10.1111/jvh.12578. Epub 2016 Aug 8.

PMID:
27500382
44.

Investigation of NS3 Protease Resistance-Associated Variants and Phenotypes for the Prediction of Treatment Response to HCV Triple Therapy.

Dietz J, Rupp D, Susser S, Vermehren J, Peiffer KH, Filmann N, Bon D, Kuntzen T, Mauss S, Grammatikos G, Perner D, Berkowski C, Herrmann E, Zeuzem S, Bartenschlager R, Sarrazin C.

PLoS One. 2016 Jun 9;11(6):e0156731. doi: 10.1371/journal.pone.0156731. eCollection 2016.

45.

Clinical value of on-treatment HCV RNA levels during different sofosbuvir-based antiviral regimens.

Maasoumy B, Vermehren J, Welker MW, Bremer B, Perner D, Höner Zu Siederdissen C, Deterding K, Lehmann P, Cloherty G, Reinhardt B, Pawlotsky JM, Manns MP, Zeuzem S, Cornberg M, Wedemeyer H, Sarrazin C.

J Hepatol. 2016 Sep;65(3):473-82. doi: 10.1016/j.jhep.2016.04.006. Epub 2016 Apr 13.

PMID:
27085252
46.

Applicability of Hepatitis C Virus RNA Viral Load Thresholds for 8-Week Treatments in Patients With Chronic Hepatitis C Virus Genotype 1 Infection.

Vermehren J, Maasoumy B, Maan R, Cloherty G, Berkowski C, Feld JJ, Cornberg M, Pawlotsky JM, Zeuzem S, Manns MP, Sarrazin C, Wedemeyer H.

Clin Infect Dis. 2016 May 15;62(10):1228-1234. doi: 10.1093/cid/ciw061. Epub 2016 Feb 9.

PMID:
26908802
47.

New HCV Therapies and Liver Transplantation.

Werner JM, Vermehren J.

Transplantation. 2016 Feb;100(2):260-1. doi: 10.1097/TP.0000000000001092. Review. No abstract available.

PMID:
26813409
48.

Lactic acidosis in patients with hepatitis C virus cirrhosis and combined ribavirin/sofosbuvir treatment.

Welker MW, Luhne S, Lange CM, Vermehren J, Farnik H, Herrmann E, Welzel T, Zeuzem S, Sarrazin C.

J Hepatol. 2016 Apr;64(4):790-9. doi: 10.1016/j.jhep.2015.11.034. Epub 2015 Nov 30.

PMID:
26658684
49.

Brain Mapping-Based Model of Δ(9)-Tetrahydrocannabinol Effects on Connectivity in the Pain Matrix.

Walter C, Oertel BG, Felden L, Kell CA, Nöth U, Vermehren J, Kaiser J, Deichmann R, Lötsch J.

Neuropsychopharmacology. 2016 May;41(6):1659-69. doi: 10.1038/npp.2015.336. Epub 2015 Oct 30.

50.

Interferon lambda 4 genotypes and resistance-associated variants in patients infected with hepatitis C virus genotypes 1 and 3.

Peiffer KH, Sommer L, Susser S, Vermehren J, Herrmann E, Döring M, Dietz J, Perner D, Berkowski C, Zeuzem S, Sarrazin C.

Hepatology. 2016 Jan;63(1):63-73. doi: 10.1002/hep.28255. Epub 2015 Nov 25.

PMID:
26406534

Supplemental Content

Loading ...
Support Center